Moderna’s COVID-19 vaccine brought in more than $4 billion in second-quarter sales, helping to push the vaccine developer into a profit.

The company also said Thursday that an analysis showed that its vaccine remains 93% effective as much as six months after the second dose.

The COVID-19 vaccine is Moderna’s only commercially approved product. It also is in the early stages of clinical testing to develop several vaccines that aim to guard against the flu, Zika and HIV among other viruses. The company also is testing a potential booster shot for the COVID-19 vaccine.

Overall, Moderna earned $2.78 billion in the second quarter, compared with a loss of $117,000 last year.